From:
`To:
`Cc:
`Subject:
`Date:
`
`Donovan, Bindu
`White, Brandon (WDC); JANS-ZYTIGA; Sidley Zytiga IPR Team
`Beel, Bryan D. (POR); *Abiraterone; Varughese, Dennies (NON-SIDLEY @SKGF.COM); "Christopher M. Gallo"; Deborah Sterling; Krause, Todd
`RE: IPR2016-01332
`Thursday, March 09, 2017 4:12:43 PM
`
`Brandon,
` 
`Janssen does not agree that we need to provide deposition dates for Drs. de Bono, Serels, Ratain, and Dorin in IPR2016-
`01332.  Exhibits 2118, 2120, 2122, 2124, 2125, 2127, and 2037 were not prepared for purposes of the instant inter partes
`review, but rather constitute “preexisting documentary evidence that was filed previously in another proceeding” for
`which cross-examination of the witnesses is not provided as routine discovery under 37 C.F.R. §42.51(b)(1)(ii).  Gea Process
`Engineering, Inc. v. Steuben Foods, Inc., IPR2014-00041, Paper 41 at 3 (PTAB June 11, 2014) (citing CBS Interactive Inc. v.
`Helferich Patent Licensing, LLC, IPR2013-00033 (Paper 85 at 2)).
` 
`Set forth below are dates for the depositions of Patent Owner’s Declarants.  Mylan/Wockhardt previously advised us that
`the dates for Dr. Rettig and Dr. Auchus are acceptable.
`Dr. Auchus: March 22 (NY)
`Dr. Vellturo: March 23 (Washington D.C.)
`Dr. Rettig: March 31 (NY)
`Dr. Judson: April 4 (London)
`
` 
`Best regards, Bindu
` 
`BINDU DONOVAN
`Partner
`
`SIDLEY AUSTIN LLP
`+1 212 839 8742
`bdonovan@sidley.com
`
`
`From: White, Brandon (Perkins Coie) [mailto:BMWhite@perkinscoie.com]
`Sent: Thursday, March 09, 2017 10:30 AM
`To: JANS-ZYTIGA; Sidley Zytiga IPR Team
`Cc: Beel, Bryan D. (Perkins Coie); Abiraterone@perkinscoie.com
`Subject: IPR2016-01332
` 
`Bindu,
`
`Patent Owner’s Response in the Mylan IPR trial affirmatively relies on the testimony of numerous fact and expert
`witnesses who have not yet been deposed in this proceeding, and for whom Janssen has not yet provided a deposition date.
`
`First, Janssen relied on the declaration testimony of Dr. Vellturo (JSN 2044), Dr. de Bono (JSN 2118), Dr. Judson (JSN
`2028) and Dr. Serels (JSN 2120, JSN 2122). Second, Janssen relied on the deposition testimony of Dr. Serels (JSN 2037,
`JSN 2127), Dr. Ratain (JSN 2124), and Dr. Dorin (JSN 2125). Regarding Drs. Serels, Ratain, and Dorin (i.e., the
`Amerigen witnesses), Mylan previously made clear its objections to Janssen relying on these witnesses, whom Mylan had
`no opportunity to cross-examine, and upon whom Mylan did not rely in its petition. For example, we noted that Janssen
`prohibited Mylan from attending the Amerigen depositions. We also note that Janssen earlier argued extensively that the
`Mylan IPR is so different from the Amerigen IPR that they could not possibly be joined, despite now arguing just the
`opposite, undermining Janssen’s position that the Amerigen evidence should be admitted here.
`
`Now that Janssen has affirmatively relied on Amerigen’s witnesses in this proceeding, Mylan expects that Janssen will
`make these declarants and deponents available for cross-examination by Mylan before April 3, 2017.
`
`Given the expedited scheduling, please provide dates for the depositions of these witness in the United States by the close
`of business today, or identify every declarant or witness for whom Janssen refuses to provide a deposition date.
`
`Mylan reserves the right to object to all declarations and transcripts relied upon in the Patent Owner Response and to seek
`relief from the Board for failure to make declarants and witnesses available for cross examination.
`
`
`
`Brandon White | Perkins Coie LLP
`PARTNER
`700 Thirteenth Street, N.W. Suite 600
`Washington, DC 20005-3960
`
`MYLAN PHARMS. INC. EXHIBIT 1149 PAGE 1
`
`

`

`D. +1.202.654.6206
`F. +1.202.654.9681
`E. BMWhite@perkinscoie.com
`
`
`NOTICE: This communication may contain privileged or other confidential information. If you have received it in error, please advise the sender by reply email and
`immediately delete the message and any attachments without copying or disclosing the contents. Thank you.
`
`
`
`****************************************************************************************************
`
`This e-mail is sent by a law firm and may contain information that is privileged or confidential.
`If you are not the intended recipient, please delete the e-mail and any attachments and notify us
`immediately.
`
`****************************************************************************************************
`
`MYLAN PHARMS. INC. EXHIBIT 1149 PAGE 2
`
`